New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2013
20:30 EDTSCMPSucampo receives $10M milestone payment from Takeda
Sucampo Pharmaceuticals announced that it has received a $10M milestone payment from Takeda, pursuant to the existing collaboration and license agreement between SPI and Takeda. The milestone payment was triggered by the commercial launch of AMITIZA in the United States for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. This is the third indication for AMITIZA.
News For SCMP From The Last 14 Days
Check below for free stories on SCMP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
16:40 EDTSCMPSucampo announces exclusive manufacturing, supply agreement for Lubiprostone
Sucampo Pharmaceuticals (SCMP) announced that its subsidiary, Sucampo AG, has signed an exclusive global manufacturing and supply agreement, or EMSA, with its manufacturing and development partner, R-Tech Ueno, for clinical and commercial supplies of AMITIZA, or lubiprostone, in most global markets. Under the new EMSA, Sucampo receives a new, lower price for certain components of or finished product of lubiprostone globally, except for the U.S. and Canada until the collaboration and license agreement with Takeda Pharmaceutical Company (TKPYY), expires in December 31, 2020, and except for Japan until the manufacturing and supply agreement for Japan expires or certain material circumstances occur. Additionally, under the EMSA Sucampo has the right to qualify a back-up supplier for lubiprostone in expanded circumstances, such as an authorized generic, additional formulations, and/or inability to supply product in certain circumstances, among others. The new EMSA supersedes the current manufacturing and supply agreements with R-Tech except in those situations noted above and is effective as of January 1.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use